Validation of nigrostriatal positron emission tomography measures: Critical limits

Annals of Neurology

Volumn 73, Issue 3, 2013, Pages 390-396

  Karimi, Morvarid ^a   Tian, Linlin ^a   Brown, Christopher A ^a   Flores, Hubert P ^a   Loftin, Susan K ^a   Videen, Tom O ^a,b   Moerlein, Stephen M ^a,b   Perlmutter, Joel S ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 6 FLUORODOPA F 18; DIHYDROTETRABENAZINE; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; IN VITRO STUDY; INTERNAL CAROTID ARTERY; MACACA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VALIDATION PROCESS;

ANIMALS; COCAINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; MPTP POISONING; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SUBSTANTIA NIGRA; TETRABENAZINE;

EID: 84876479290     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23798     Document Type: Article

References (31)

1. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003; 184 (suppl 1): S68-S79.
2. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
3. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64: 208-215.
4. Biglan KM, Holloway RG,. Surrogate endpoints in Parkinson's disease research. Curr Neurol Neurosci Rep 2003; 3: 314-320.
5. Dorsey ER, Holloway RG, Ravina BM,. Biomarkers in Parkinson's disease. Expert Rev Neurother 2006; 6: 823-831.
6. Tabbal SD, Mink JW, Antenor JA, et al. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine. Neuroscience 2006; 141: 1281-1287.
7. Tai YC, Ruangma A, Rowland D, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 2005; 46: 455-463.
8. Rowland DJ, Garbow JR, Laforest R, Snyder AZ,. Registration of [18F]FDG microPET and small-animal MRI. Nucl Med Biol 2005; 32: 567-572.
9. Patlak CS, Blasberg RG,. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
10. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
11. Tian L, Karimi M, Loftin SK, et al. No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. PLoS One 2012; 7: e31439.
12. Karimi M, Carl JL, Loftin S, Perlmutter JS,. Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid. J Chromatogr B Biomed Sci Appl 2006; 836: 120-123.
13. Tabbal SD, Tian L, Karimi M, et al. Low nigrostriatal reserve for motor parkinsonism in nonhuman primates. Exp Neurol 2012; 237: 355-362.
14. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34: 324-330.
15. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993; 34: 331-338.
16. Yee RE, Irwin I, Milonas C, et al. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord 2001; 16: 838-848.
17. Masilamoni G, Votaw J, Howell L, et al. (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Exp Neurol 2010; 226: 265-273.
18. Alvarez-Fischer D, Blessmann G, Trosowski C, et al. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. Neuroimage 2007; 38: 5-12.
19. Gleave JA, Farncombe TH, Saab C, Doering LC,. Correlative single photon emission computed tomography imaging of [(123)I]altropane binding in the rat model of Parkinson's. Nucl Med Biol 2011; 38: 741-749.
20. Piccini P, Pavese N, Brooks DJ,. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 2003; 53: 647-653.
21. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47: 493-503.
22. Chen MK, Kuwabara H, Zhou Y, et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 2008; 105: 78-90.
23. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-718.
24. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459-466.
25. Martin WR, Wieler M, Stoessl AJ, Schulzer M,. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol 2008; 63: 388-394.
26. Helmich RC, Derikx LC, Bakker M, et al. Spatial Remapping of Cortico-striatal Connectivity in Parkinson's Disease. Cereb Cortex 2010; 20: 1175-1186.
27. Tang CC, Poston KL, Dhawan V, Eidelberg D,. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 2010; 30: 1049-1056.
28. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134.
29. Perlmutter JS, Tempel LW, Black KJ, et al. MPTP induces dystonia and parkinsonism: clues to the pathophysiology of dystonia. Neurology 1997; 49: 1432-1438.
30. Meissner W, Prunier C, Guilloteau D, et al. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol Neurobiol 2003; 28: 209-218.
31. Burke RE,. Intracellular signalling pathways in dopamine cell death and axonal degeneration. Prog Brain Res 2010; 183: 79-97.